Cytek Biosciences, Inc. CTKB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 51.8%-3.6pp | 55.4%-1.3pp | 56.7%-4.9pp | 61.6%-0.3pp | |
| Operating margin | -20%— | —— | -14.4%-13.3pp | -1.2%-8.3pp | |
| Net margin | -33%— | —— | —— | 1.5%— | |
| Returns | |||||
| Return on equity | -18%— | —— | —— | 0.6%— | |
| Return on invested capital | -12.6%— | —— | -14.4%-12.6pp | -1.9%— | |
| Efficiency | |||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.3×0.0× | |
| Liquidity | |||||
| Current ratio | 5×-0.8× | 5.9×-1.1× | 7×-2.3× | 9.3×-3.8× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $2.68-11.7% | $3.03+4.3% | $2.91-5.4% | $3.07-38.2% | |
| Valuation | |||||
| Market capitalization | $577.27M+54.5% | $835.98M-29.9% | $1.19B-13.7% | $1.38B-36.8% | |
| Price / sales | 2.8×+0.9× | 4.2×-2.0× | 6.2×-2.2× | 8.4×-8.7× | |
| Price / book | 1.8×+0.8× | 2.1×-0.9× | 3×-0.2× | 3.2×-2.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cytek Biosciences, Inc.'s profit margins?
- Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
- Where do Cytek Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
